Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Cesar Vargas-Serafin"'
Publikováno v:
Transplantation and Cellular Therapy. 28:S349-S350
Autor:
Kevin Teran-De-la-Sancha, Cesar Vargas-Serafin, Jesus Delgado-de-la-Mora, Aldo A. Acosta-Medina, Christianne Bourlon, Maria T Bourlon
Publikováno v:
The American journal of hospicepalliative care. 38(8)
Background: Myelophthisis (MPT) has been associated with a dreadful prognosis. Patients’ access to palliative care (PC) and factors influencing its clinical outcomes are poorly described. Our aim was to analyze the impact of patient- and disease-sp
Autor:
Deborah Martínez-Baños, Aldo A. Acosta-Medina, Cesar Vargas-Serafin, Christianne Bourlon, Irvin Ordoñez-González
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(3)
Background Outcomes of newly diagnosed multiple myeloma (NDMM) in developing regions have not paralleled those in developed settings. Economic disadvantage, comorbidities, and aggressive disease behavior play competing roles on defining outcomes. Our
Autor:
Christianne Bourlon, Elena Tuna-Aguilar, C.F. Hernández-Mata, Alvaro Aguayo, Maria T Bourlon, Cesar Vargas-Serafin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 16:453-459
The cytogenetic hallmark of chronic myeloid leukemia (CML) is the Philadelphia chromosome. Monitoring the response in patients receiving therapy is a standard of care. The present study was conducted to assess the monitoring adherence and reliablenes
Publikováno v:
Clinical Case Reports
Key Clinical Message Nontuberculous mycobacteria infrequently cause disseminated infections in immunocompetent hosts. However, they are increasingly being recognized in immunocompromised patients. We present the case of a 40-year-old HIV-positive mal
Publikováno v:
Blood. 134:5533-5533
Introduction In the last decades Multiple Myeloma (MM) has had a surge in clinical research and novel therapies with a subsequent impact in clinical outcomes. Nonetheless, these changes have stagnated and remain slow-occurring in populations without
Autor:
Juan Rangel-Patiño, Cesar Vargas-Serafin, Daniela Perez-Samano, Deborah Martínez-Baños, Aldo A. Acosta-Medina, Christianne Bourlon
Publikováno v:
Blood. 134:5527-5527
Introduction Extramedullary myeloma (EMM) is the synchronous presence of clonal plasma cells (CPC) in both bone marrow and distant sites. Its frequency is reported among 6-20% of multiple myeloma (MM) patients and can manifest as osseous plasmacytoma
Autor:
Andrés Gómez-De León, Lourdes Gil-Flores, Perla Colunga-Pedraza, Christianne Bourlon, César Vargas-Serafín, María de los Ángeles del Campo-Martínez, Alberto Olaya-Vargas, Martín Pérez-García, Xitlaly J. González-Leal, Miguel Angel Herrera Rojas, Sergio Lozano-Rodríguez, Manuel Solano-Genesta, Anna Cecilia Rodríguez-Zúñiga, Alexia Sánchez-Arteaga, Guillermo J. Ruiz-Argüelles, David Gómez-Almaguer
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 1294-1300 (2022)
ABSTRACTObjective: To analyze the number of HSCTs performed in 2019 vs. 2020 and report the status of transplant centers (TCs) during and a year after the COVID-19 pandemic.Methods: We performed a comprehensive cross-sectional nationwide study includ
Externí odkaz:
https://doaj.org/article/32b5f389575146d7a3191676937dc91f
Publikováno v:
Blood. 126:5327-5327
Background In Western populations the change on incidence rates during time, demographic characteristics and impact of novel therapies in the outcome of patients with multiple myeloma (MM), is well described. Some studies suggest that rates and clini
Autor:
Renata Rivera, Cesar Vargas-Serafin, Guadalupe Jiménez, Olga Barrales, Georgina Barrera, Osvaldo Mutchinick, Christianne Bourlon, Deborah Martínez-Baños, Virginia Santiago-Cano
Publikováno v:
Blood. 124:5709-5709
Background Multiple myeloma (MM) has been associated with several cytogenetic abnormalities (CA), contributing in heterogeneity of clinical outcome. CA are not always captured by conventional cytogenetic analysis (CGA), fluorescence in situ hybridiza